FMP
NASDAQ
10.62 USD
-0.38 (-3.58%)
Mr. Daniel W. Paterson
Healthcare
Biotechnology
https://www.verastem.com
NASDAQ
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 20...
0001526119
US92337C2035
92337C104
117 Kendrick Street
781 292 4200
US
57
Jan 27, 2012
0001526119
NASDAQ
Biotechnology
Healthcare
92337C104
US92337C2035
US
10.62
0.49
133.54k
268.64M
-
4.2-15.12
1.69
-
-
-
-
-2.68
-
https://www.verastem.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.